Evolus (NASDAQ:EOLS) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Evolus (NASDAQ:EOLS) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $22.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, November 7th.

Evolus Stock Performance

EOLS opened at $13.48 on Tuesday. The stock’s 50 day simple moving average is $11.67 and its 200-day simple moving average is $13.74. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a market cap of $853.57 million, a PE ratio of -14.81 and a beta of 1.32. Evolus has a 1 year low of $9.25 and a 1 year high of $17.82.

Institutional Trading of Evolus

Several institutional investors have recently bought and sold shares of the stock. Barclays PLC boosted its stake in shares of Evolus by 268.0% in the 3rd quarter. Barclays PLC now owns 93,662 shares of the company’s stock valued at $1,518,000 after purchasing an additional 68,213 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Evolus by 173.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after purchasing an additional 265,635 shares during the last quarter. Armistice Capital LLC acquired a new stake in shares of Evolus in the second quarter valued at $3,906,000. Jane Street Group LLC raised its holdings in shares of Evolus by 47.0% in the third quarter. Jane Street Group LLC now owns 91,899 shares of the company’s stock valued at $1,489,000 after buying an additional 29,396 shares during the last quarter. Finally, Lord Abbett & CO. LLC lifted its position in Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after buying an additional 188,685 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.